Shire sees 24 per cent rise in revenues
Demand for hyperactivity drugs in the US drove a 24 per cent rise in third-quarter revenues for Shire.
The specialist pharmaceutical firm said its total revenues rose to $1.09bn between July and September as product sales surged by 28 per cent to $1.02bn. Alongside demand for its hyperactivity treatments, Shire also reported strong sales for its rare disease medicines. Sales of its Vyvanse attention deficit hyperactivity disorder drug were up by 32 per cent to about $200m. Drawing strength from the results, Shire chief executive Angus Russell said the company was on track to meet market expectations for the full year.
Subscribe to Independent Premium to bookmark this article
Want to bookmark your favourite articles and stories to read or reference later? Start your Independent Premium subscription today.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies